Advertisement

Nonseminomatous Germ Cell Tumors

Part of the Medical Radiology book series (MEDRAD)

Abstract

Germ cell tumors are derived from the malignant transformation of preanaphase I germ cells. These tumors most commonly originate in the gonads (testis or ovary) but similar neoplasms occasionally originate in midline structures (retroperitoneum, mediastinum, or pineal gland). Rarely, a germ cell tumor may originate in other sites. Many retroperitoneal germ cell tumors probably originate in occult testis primary sites whereas mediastinal germ cell tumors are likely distinct entities that arise in the mediastinum.

Keywords

Germ Cell Tumor Proc ASCO Nonseminomatous Germ Cell Tumor Pure Seminoma Testicular Germ Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Atkin N, Baker M (1983) i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis? Cancer Genet Cytogenet 10: 199–204Google Scholar
  2. Bajorin DF, Mortzer RJ, Rodriquez E, Murphy B, Bosl GJ (1993) Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85: 60–62PubMedCrossRefGoogle Scholar
  3. Batata M, Chu F, Hilaris B, Whitmore W, Golbey R (1982) Testicular cancer in cryptorchids. Cancer 49: 1023–1030PubMedCrossRefGoogle Scholar
  4. Beyer J, Schwella N, Zingsem J, et al. (1995) Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a ran¬domized comparison. J Clin Oncol 13: 1328–1335PubMedGoogle Scholar
  5. Bosl GJ, Ilson DH, Rodriguez E, Motzer RJ, Reuter V, Chaganti RSK (1994) Clinical relevance of the i(12p) marker chro¬mosome in germ cell tumors. J Natl Cancer Inst 86: 349–355PubMedCrossRefGoogle Scholar
  6. Bosl G, Sheinfeld J, Bojorin DF, Motzer R (1997) Cancer of the testis. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, PhiladelphiaGoogle Scholar
  7. Chaganti RSK, Rodriguez F, Bosl GJ (1993) Cytogenetics of male germ cell tumors. Urol Clin North Am 20: 55–66PubMedGoogle Scholar
  8. Cullen M, Stenning S, Parkinson M, et al. (1995) Short course adjuvant chemotherapy in high risk stage I nonse- minomatous germ cell tumours of the testis (NSGCTT): an MRC(UK) study report [abstract]. Proc ASCO 14: 244Google Scholar
  9. Daugaard G, von der Masse H, Olsen J, Rorth M, Skakkebaek NE (1987) Carcinoma-in-situ of the testis in patients with assumed extragonadal germ-cell tumors. Lancet 11: 528–530CrossRefGoogle Scholar
  10. Davis B, Herr H, Fair W, Bosl GJ (1994) The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy. J Urol 152: 111–113PubMedGoogle Scholar
  11. Donohue J, Rowland R, Kopecky K, et al. (1987) Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis tumor. J Urol 137: 1176–1179PubMedGoogle Scholar
  12. Dunphy C, Ayala A, Swanson D, Ro J, Logothetis C (1988) Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. Cancer 62: 1202–1206PubMedCrossRefGoogle Scholar
  13. Einhorn LH, Weathers T, Loehrer P, Nichols C (1996) Long- term follow up of second line chemotherapy with vin¬blastine, ifosfamide, and cisplatin in disseminated germ cell tumors [abstract]. Proc ASCO 15: 240Google Scholar
  14. Fossa SD, Qvist H, Stenwig AF, et al. (1992) Is post chemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 10: 569–573PubMedGoogle Scholar
  15. Gels M, Hoekstra H, Sleijfer D, et al. (1995) Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further followup: a single center 10-year experience. J Clin Oncol 13: 1188–1194PubMedGoogle Scholar
  16. Gietema J, Sleijfer D, Willemse P, et al. (1992) Long term follow up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 116: 709–715PubMedGoogle Scholar
  17. Harstrick A, Schmoll HJ, Wilke H, et al. (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 9: 1549–1555PubMedGoogle Scholar
  18. Hartlapp JH, Weissbach I, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 10: 277–284PubMedCrossRefGoogle Scholar
  19. Kaye SB, Mead GM, Fossa S, et al. (1995) An MCR/EORTC randomized trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP [abstract]. Proc ASCO 14: 246Google Scholar
  20. Linkesch W, Krainer M, Wagner A (1992) Phase I/II trail of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed nonseminomatous germ cell tumors. Bone Marrow Transplant 10 (Suppl 2); 28Google Scholar
  21. Motzer RJ, Bjorin DF, Valamis V, Weisen S, Bosl GJ (1992a) Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center Experience. Semin Oncol 19: 8–11PubMedGoogle Scholar
  22. Motzer RJ, Gulati SC, Crown JP, et al. (1992b) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: early intervention is better tolerated. Cancer 69: 550–556PubMedCrossRefGoogle Scholar
  23. Motzer RJ, Bjorin DF, Bosl GJ (1992c) “Poor-risk” germ cell tumors: current progress and future directors. Semin Oncol 19:206–214Google Scholar
  24. Motzer RJ, Gulati SC, Tong WP, et al. (1993) Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53: 3730–3735PubMedGoogle Scholar
  25. Motzer RJ, Sheinfeld J, Mazumdar M, et al. (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13: 2700–2704PubMedGoogle Scholar
  26. Nichols CR, Breeden ES, Leohrer PJ (1992) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85: 36–40Google Scholar
  27. Nicolai N, Pizzocaro G (1995) A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10 year followup. J Urol 154: 1045–1049PubMedCrossRefGoogle Scholar
  28. Oliver RTD, Raja M, Ong J, Gallagher C (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I patients. J Urol 148: 1453–1455PubMedGoogle Scholar
  29. Pedersen-Bjergaard J, Hansen ST, Larsen SO, Daugaard G, Philip R, Rorth M (1991) Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet 338: 359–363PubMedCrossRefGoogle Scholar
  30. Pizzocaro G, Piva L, Salvioni R, Pasi M, Pilotti S, Monfardinai S (1984a) Adjuvant chemotherapy in resected stage II nonseminomatous germ cell tumors of the testis. In which cases is it necessary? Eur Urol 10: 151–158Google Scholar
  31. Pizzocaro G, Zanoni F, Milani A, et al. (1984b) Retroperitoneal lymphadenectomy and aggressive chemotherapy in non-bulky clinical stage II nonseminomatous germinal testis tumors. Cancer 53: 1363–1368PubMedCrossRefGoogle Scholar
  32. Pont J, Albrecht W, Postner G, et al. (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14: 441–448PubMedGoogle Scholar
  33. Read G, Stenning S, Cullen M, et al. (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10: 1762–1768PubMedGoogle Scholar
  34. Rodriguez E, Mathew S, Reuter V, et al. (1992) Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 52: 2285–2291PubMedGoogle Scholar
  35. Skinner DG, Scardino PT (1980) Relevance of biochemical tumor markers and lymphadenectomy in management of nonseminomatous testis tumors: current perspective. J Urol 123: 378–382PubMedGoogle Scholar
  36. Stephenson W, Poirier S, Rubin L, Einhorn I (1995) Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 13: 2278–2280PubMedGoogle Scholar
  37. Vos A, Oosterhuis W, de Jong B, Buist J, Koops H (1990) Cytogenetics of carcinoma in situ of the testis. Cancer Genet Cytogenet 46: 75–81Google Scholar
  38. Williams S (1998) Germ cell tumors. In: Cheson BD (ed) Williams S I V. American College of PhysiciansGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • H. Ozer
    • 1
  1. 1.Department of MedicineAllegheny University HospitalsPhiladelphiaUSA

Personalised recommendations